Dan Ryder (@DanRyder3) profile picture

Founder & Managing Director at Bridge Informatics. I'm passionate about #informatics, #datainfrastructure, #biostatistics, #drugdiscovery, #bioinformatics.

Boston, MA
Joined March 2012
ICYMI: We delved into groundbreaking research that harnessed #AI deep learning models to decipher the intricate “enhancer codes” hidden within our DNA. These enhancer codes play a crucial role in controlling cell identity. Read more: bridgeinformatics.com/ai-dee…
1
2
107
ICYMI: A new computational tool, MERCI, has the potential to reshape oncological research and prognostic assessments: bridgeinformatics.com/target… #MitochondrialTransfer #CancerResearch #MERCIAlgorithm #LifeSciences
2
2
85
This turned out to be a really fun conference!
We presented a poster at #BioITExpo last week on a single-cell RNA sequencing (scRNA-seq) analysis we performed. Click here to view the poster and see how we dissected transcriptional profiles of complex biological systems at a single cell level: bridgeinformatics.com/poster…
1
85
We presented a poster at #BioITExpo last week on a single-cell RNA sequencing (scRNA-seq) analysis we performed. Click here to view the poster and see how we dissected transcriptional profiles of complex biological systems at a single cell level: bridgeinformatics.com/poster…
1
1
1
189
We’re here at #BioIT2024 in Boston! Come visit us at poster # 8 where we’re presenting on how to move from raw sequencing data to fully annotated cell clusters using #singlecell #RNAseq #singlecell
1
4
132
Ribbon bling is a bit out of hand this year
4
1
58
5,075
Today we should celebrate the perseverance of $VRTX in translating the incredible human genetics of Nav 1.8 for pain into a drug with Phaase 3 data ready for approval. The commercial market can debate the differentiation and merits vs existing generics, but it should be a huge celebration for novel science and the value of the genetic validation of targets in drug discovery - which instills the confidence in expensive, long-term, multi-candidate R&D programs against these genetic targets.
7
15
5
190
50,207
Hospital in Spain offers home-brewed CAR-T cell therapy at 1/3 of commercial cost. Hospitals can’t manufacture most medicines. But for CAR-T, patients’ own cells are removed + reprogrammed + returned to kill cancer. “The process is the product” 🇪🇸 🧫 statnews.com/2023/12/19/car-…
4
11
4
59
7,616
ICYMI: Can bacteria be living biosensors? Read about the remarkable approach of engineering bacteria to detect cancerous DNA in models of colorectal cancer in our blog: bridgeinformatics.com/harnes…
1
1
130
As researchers continue to uncover connections between mind & body, they're better equipped to develop more effective treatment strategies. Today’s blog explores how stress management could enhance treatment success for IBD patients: bridgeinformatics.com/blog
1
1
87
ICYMI: Have you read about the newest applications for uncovering the architecture of gene regulatory networks? Last month's blog explains what they are and how to use them: lnkd.in/g6dyumXM #bioinformatics #bridgeinformatics
1
2
99
AAV-Perturb-seq allows researchers to peer into the intricate world of geneotype to phenotype correlations with unprecedented precision. Learn more in today’s blog: bridgeinformatics.com/an-in-…
1
1
97
ICYMI: How can CAR-T therapy be applied to new cancer types? In a recent paper, researchers analyzed RNA-Seq data for novel, safe targets to treat acute myeloid leukemia (AML). Read more on BI's blog: ow.ly/E6LX50PIeTE
2
1
144
This conference is very engaging, such a pleasant surprise. Most interesting topics so far: hype around AI, what LPs think about funding VC in this environment, what your posture over Zoom says about you, and DEI in startup environment. #ack2023
1
2
76
Excellent (and engaging) conversations going on so far at the Nantucket Conference. Thanks @ScottKirsner et al for making it happen! #ack2023
1
77
We are proud to showcase our progress at SITC’s annual meeting this November. Poster #1001 “CAT-248 demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors” will be presented at #SITC23 on Friday Nov 3rd!
1
3
9
487
Really excited about my upcoming course on #python for #datascience automation. Many companies are shifting to python for process automation. You’ll learn how in my course. Learn more. buff.ly/3439K41 PS - It’s great for #rstats users that want to learn Python.
6
20
The eternal biotech startup conundrum: should I invest in building platform 🏗, products 💊 or partnerships 🤝? Conventional wisdom: choose 2 (that aren’t platform). We finally have the rise of true bio platform co’s; #BioTwitter: examples of early co’s that balance all 3?
13
6
1
56
Dan Ryder retweeted
FDA advisory committee votes 5-3 to maintain Merck's Keytruda (pembrolizumab) accelerated approval for urothelial carcinoma.
1
13
1
29